Latest news with #FAHA
Yahoo
3 days ago
- Health
- Yahoo
Dr. Jennifer Ashton and Dr. Joseph Woo join American Heart Association Board of Directors
(NewMediaWire) - July 16, 2025 - DALLAS The American Heart Association, the world's leading nonprofit organization focused on heart and brain health for all, announces the appointment of two leading health and science leaders, Jennifer Ashton, M.D., M.S. and Joseph Woo, M.D., FAHA, to its volunteer Board of Directors, effective July 1, 2025. Dr. Ashton and Dr. Woo bring clinical leadership, health media influence and scientific innovation to the Association as it enters its second century, intensifying its efforts to change the future of health and improve cardiovascular and cerebrovascular health outcomes, which continue to be leading causes of death in the United States. Double board-certified in Ob-Gyn and obesity medicine, Dr. Jennifer Ashton is a nationally recognized women's health advocate known for communicating complex medical topics in an accessible way. As ABC News' Chief Medical Correspondent, she became a nationally trusted voice during major public health events, including the COVID-19 pandemic. A Columbia duPont and Emmy Award-winning journalist, a bestselling author and champion of preventive health and mental wellness, Dr. Ashton has volunteered with the American Heart Association for more than a decade, frequently speaking at local Go Red for Women(R) events. She has received numerous honors from the Association, including the 2024 Heart Saver Hero Award, the 2023 "Woman Changing the World Award" and the Go Red for Women Award in 2018. These accolades reflect her tireless advocacy for women's cardiovascular health and her leadership in advancing the Association's mission through education and action. "As the obesity and maternal mortality epidemics are two of the most pressing issues affecting women in the U.S., and since both have cardiovascular associations, I hope that my experience and expertise in these fields can assist the American Heart Association's efforts," Ashton said. "And, as the daughter of a cardiologist, I am honored to be the first OB-GYN appointed to the Board in the history of the Association." As a board-certified cardiothoracic surgeon, cardiovascular surgeon and transplant surgeon, Dr. Joseph Woo is a nationally recognized leader and educator in cardiac surgery innovation. He is professor and chair of the Stanford Medicine Department of Cardiothoracic Surgery, associate director of the Stanford Cardiovascular Institute and the Norman E. Shumway Professor of Cardiothoracic Surgery. He has pioneered advanced surgical research on multiple studies and clinical trials, including numerous National Institutes of Health (NIH) grant projects, as well as American Heart Association grants to study ways to treat heart failure through cellular repair. In 2021, he received the Association's Clinical Research Prize for his groundbreaking work in minimally invasive heart valve repair. Earlier in his career, he received the Vivien Thomas Young Investigator Award (1997) for postdoctoral research on molecular strategies to reduce myocardial ischemic injury. Dr. Woo holds patents for several heart-related medical devices and surgical techniques and has co-authored over 490 peer-reviewed papers. Beyond his research, he is deeply committed to mentorship, global collaboration and advancing medical education in cardiovascular health. "As a physician-scientist, I have been a daily witness to the tragedy of cardiovascular disease on human life, and also to the triumph of improving health and saving lives through scientific discovery," Woo said. "The American Heart Association is a global leader in supporting vital research and establishing the best evidenced-based approaches to cardiovascular health and treatment grounded in basic science, engineering, translational and clinical investigation. I look forward to continuing to support the Association as we continue our bold endeavors toward a healthier world for all." "We are honored to welcome Dr. Jen Ashton and Dr. Joe Woo to our Board of Directors," said Nancy Brown, CEO of the American Heart Association. "Dr. Ashton's national media profile, influence and dedication to preventive health, alongside Dr. Woo's groundbreaking work in cardiovascular surgery and academic leadership, uniquely position them to help us change the future of health and drive forward our mission. Their perspectives will be instrumental as we continue our work to bring health and hope to everyone, everywhere." These appointments reflect the American Heart Association's continued commitment to science-based solutions, community-centered approaches and bold leadership in the fight against heart disease and stroke. The American Heart Association's Board of Directors is the organization's top volunteer governing body, working closely with CEO Nancy Brown to provide strategic oversight and financial stewardship to advance the organization's mission of longer, healthier lives for all. Board members also serve as ambassadors, leveraging their individual professional expertise and networks of influence to further extend, accelerate and elevate the Association's visibility, impact and collaborations. Additional Resources Multimedia is available on the right column of release link. Learn more about the American Heart Association's 2025-26 volunteer and staff leadership. Follow AHA/ASA news on X @HeartNews ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173 Suzanne Grant: For Public Inquiries: 1-800-AHA-USA1 (242-8721) and Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 days ago
- Health
- Associated Press
Dr. Jennifer Ashton and Dr. Joseph Woo join American Heart Association Board of Directors
( NewMediaWire ) - July 16, 2025 - DALLAS — The American Heart Association, the world's leading nonprofit organization focused on heart and brain health for all, announces the appointment of two leading health and science leaders, Jennifer Ashton, M.D., M.S. and Joseph Woo, M.D., FAHA, to its volunteer Board of Directors, effective July 1, 2025. Dr. Ashton and Dr. Woo bring clinical leadership, health media influence and scientific innovation to the Association as it enters its second century, intensifying its efforts to change the future of health and improve cardiovascular and cerebrovascular health outcomes, which continue to be leading causes of death in the United States. Double board-certified in Ob-Gyn and obesity medicine, Dr. Jennifer Ashton is a nationally recognized women's health advocate known for communicating complex medical topics in an accessible way. As ABC News' Chief Medical Correspondent, she became a nationally trusted voice during major public health events, including the COVID-19 pandemic. A Columbia duPont and Emmy Award-winning journalist, a bestselling author and champion of preventive health and mental wellness, Dr. Ashton has volunteered with the American Heart Association for more than a decade, frequently speaking at local Go Red for Women(R) events. She has received numerous honors from the Association, including the 2024 Heart Saver Hero Award, the 2023 ' Woman Changing the World Award ' and the Go Red for Women Award in 2018. These accolades reflect her tireless advocacy for women's cardiovascular health and her leadership in advancing the Association's mission through education and action. 'As the obesity and maternal mortality epidemics are two of the most pressing issues affecting women in the U.S., and since both have cardiovascular associations, I hope that my experience and expertise in these fields can assist the American Heart Association's efforts,' Ashton said. 'And, as the daughter of a cardiologist, I am honored to be the first OB-GYN appointed to the Board in the history of the Association.' As a board-certified cardiothoracic surgeon, cardiovascular surgeon and transplant surgeon, Dr. Joseph Woo is a nationally recognized leader and educator in cardiac surgery innovation. He is professor and chair of the Stanford Medicine Department of Cardiothoracic Surgery, associate director of the Stanford Cardiovascular Institute and the Norman E. Shumway Professor of Cardiothoracic Surgery. He has pioneered advanced surgical research on multiple studies and clinical trials, including numerous National Institutes of Health (NIH) grant projects, as well as American Heart Association grants to study ways to treat heart failure through cellular repair. In 2021, he received the Association's Clinical Research Prize for his groundbreaking work in minimally invasive heart valve repair. Earlier in his career, he received the Vivien Thomas Young Investigator Award (1997) for postdoctoral research on molecular strategies to reduce myocardial ischemic injury. Dr. Woo holds patents for several heart-related medical devices and surgical techniques and has co-authored over 490 peer-reviewed papers. Beyond his research, he is deeply committed to mentorship, global collaboration and advancing medical education in cardiovascular health. 'As a physician-scientist, I have been a daily witness to the tragedy of cardiovascular disease on human life, and also to the triumph of improving health and saving lives through scientific discovery,' Woo said. 'The American Heart Association is a global leader in supporting vital research and establishing the best evidenced-based approaches to cardiovascular health and treatment grounded in basic science, engineering, translational and clinical investigation. I look forward to continuing to support the Association as we continue our bold endeavors toward a healthier world for all.' 'We are honored to welcome Dr. Jen Ashton and Dr. Joe Woo to our Board of Directors,' said Nancy Brown, CEO of the American Heart Association. 'Dr. Ashton's national media profile, influence and dedication to preventive health, alongside Dr. Woo's groundbreaking work in cardiovascular surgery and academic leadership, uniquely position them to help us change the future of health and drive forward our mission. Their perspectives will be instrumental as we continue our work to bring health and hope to everyone, everywhere.' These appointments reflect the American Heart Association's continued commitment to science-based solutions, community-centered approaches and bold leadership in the fight against heart disease and stroke. The American Heart Association's Board of Directors is the organization's top volunteer governing body, working closely with CEO Nancy Brown to provide strategic oversight and financial stewardship to advance the organization's mission of longer, healthier lives for all. Board members also serve as ambassadors, leveraging their individual professional expertise and networks of influence to further extend, accelerate and elevate the Association's visibility, impact and collaborations. Additional Resources ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173 Suzanne Grant: [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and
Business Wire
24-06-2025
- Health
- Business Wire
Results From the World's First Observational Study of ExoStat Medical's MicroTREND System Support P OM CO 2 as an Important Early Indicator of Septic Shock in Critically Ill Patients
PRIOR LAKE, Minn.--(BUSINESS WIRE)--ExoStat Medical, Inc. a medical device company engaged in the research and development of the novel MicroTREND System which non-invasively monitors microcirculatory tissue perfusion in real-time at the bedside announced today the successful completion of the world's first IRB-approved, ICU observational septic shock study to assess the efficacy and clinical utility of oral mucosal partial pressure CO 2 (P om CO 2) as a parameter for determining the status of microcirculatory tissue perfusion. The findings of this study concluded that data produced by the MicroTREND could, as an adjunct tool, enhance the value of data currently gathered by macrohemodynamic tools currently considered standard protocol. "This first-ever study marks a major milestone for critical care and for ExoStat,' said Wanchun Tang, MD, MCCM, FAHA, FNAI. Share Conducted at the Second Affiliated Hospital of Anhui Medical University (Hefei, China) the study enrolled 23 septic shock patients and assessed the role of bedside oral mucosa tissue monitoring P om CO 2 as an indicator of early septic shock dysfunction. The study completed a comparative analysis of current standards of care including serum lactate, now considered the gold standard for tissue perfusion evaluation. Principal Investigators of the study are currently preparing the results for near-future publication. 'This first-ever study marks a major milestone for critical care, for ExoStat, and for me as it has been a 40-year project that started with the Weil Institute in the 1980's,' said Wanchun Tang, MD, MCCM, FAHA, FNAI, and Senior Technology and Medical Advisor for ExoStat. 'For the first time ever, physicians were able to view, in real time, the very early and ongoing signs of microcirculatory dysfunction due to tissue hypoperfusion. Every moment matters in septic shock and delays can be devastating to the patient. This device can produce actuals that can provide the physician with more reaction time. It is now well-understood that the current macrohemodynamic tools do not fully capture real-time metrics of the patient under care. This study finally brought what was hypothesis into reality. It was exciting to observe.' Dr. Tang later admitted that it was difficult to see the first measures on the monitor due to tears of joy. The MicroTREND is a patented, FDA-cleared non-invasive monitoring system that detects P om CO 2 using a microsensor that sits atop the inner cheek buccal tissue. There are no needles, no blood, no catheters, and no 'lag in time' for lab work required. The importance of time cannot be overstated in treating all shock states, especially sepsis. All shock cases begin with tissue hypoperfusion. It is a common denominator. 'This study achieved the ultimate objective of ExoStat's mission which was to provide microcirculatory perfusion awareness to physicians who treat the sickest of the sick', stated Jim Hays, Chief Executive Officer of ExoStat. 'We are excited to embark now on our second phase of pre-market clinical testing being planned with iconic research institutions where we will focus on achieving a better understanding of the effect of current standards of care on microcirculation. These are exciting times indeed.' About ExoStat Medical ExoStat Medical Inc. is a privately-held medical device company located in Prior Lake, MN. The research and development quest to create the MicroTREND began in 2008 as a vision of Max Harry Weil, MD, who is often called 'the father of critical care medicine'. The technology platform developed by ExoStat provides data to enable physicians to assess and to treat microcirculatory hypoperfusion, a life-threatening medical emergency. Visit for more information.
Business Wire
08-05-2025
- Business
- Business Wire
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla.--(BUSINESS WIRE)-- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. 'In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024,' said Quang X. Pham, Chairman & CEO. 'The appointment of James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer positions us for success in reviewing potential assets to add to our portfolio and designing and executing our clinical program for tecarfarin. The finalized Collaboration Agreement with Abbott validates the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs). And our meeting with the FDA provided additional guidance in the design of a pivotal trial.' Highlights from the Quarter Ended March 31, 2025, and Other Recent Events: Leadership Advances In February 2025, Cadrenal appointed James J. Ferguson, M.D., FACC, FAHA, as Chief Medical Officer to lead the review of business development opportunities to expand the Company's pipeline and drive the late-stage clinical development of tecarfarin for conditions requiring chronic anticoagulation therapy. Regulatory Update In February 2025, Cadrenal met with the U.S. Food and Drug Administration (FDA) for a Type D meeting. The FDA provided additional guidance on the appropriate design for a Phase 3 tecarfarin trial and welcomed submission of a final study design for review. Collaboration Agreement with Abbott In March 2025, we announced a Collaboration Agreement with Abbott (NYSE: ABT) to support our pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Under the agreement, Abbott will share insights from recent HeartMate 3™ clinical trials and will support Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise. Operational Milestones During the quarter, Cadrenal successfully completed the technical transfer and manufacturing of its tecarfarin drug substance (API) from a CDMO site located in Asia to a CDMO site in the United States. This initiative was done to support the company's clinical and regulatory development strategy for tecarfarin and to improve supply chain security. Cadrenal also conducted strategic market opportunity research for multiple indications, including patients with left ventricular assist devices. This research indicates that tecarfarin is uniquely positioned to provide clinical value to patients in the rapidly growing LVAD market, which is projected to nearly double by 2032. This research also showed that tecarfarin has the potential to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients. Participation in Key Investor, Medical, and Business Development Conferences Cadrenal was active during the first quarter in several significant conferences to build corporate visibility and underscore its commitment to advancing innovation in anticoagulation therapy. Investor interactions included participation at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, a Company presentation at the BIO CEO and Investor Conference in New York, and, after the close of the quarter, a Company presentation at the Centri Capital Conference at Nasdaq headquarters in New York. Shortly after the quarter's close, Cadrenal participated in the 18 th National Conference on Anticoagulation Therapy in Washington, D.C. Strategic Development Collaborations Cadrenal continues to explore opportunities to add to the Company's clinical pipeline and collaborate with potential development partners to advance the development of tecarfarin for patients with LVADs and for other indications requiring chronic anticoagulation. First Quarter 2025 Financial Highlights Research and development expenses for the quarter ended March 31, 2025, were $1.7 million compared to $0.6 million for the same period in 2024. General and administrative expenses for the quarter ended March 31, 2025, were $2.3 million compared to $1.1 million for the same period in 2024. Cadrenal reported a net loss of $3.8 million for the quarter ending March 31, 2025, compared to $1.7 million for the same period in 2024. On March 31, 2025, Cadrenal had cash and cash equivalents of $7.3 million, compared to $10.0 million as of December 31, 2024. The Company had approximately 1.9 million shares of common stock outstanding as of March 31, 2025. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options. Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potentially,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the appointment of James Ferguson, M.D., FACC, FAHA, as the Company's Chief Medical Officer positioning the Company for success in reviewing potential assets to add to its portfolio and designing and executing its clinical program for tecarfarin; the finalized Collaboration Agreement with Abbott validating the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs); Abbott sharing insights from recent HeartMate 3™ clinical trials and supporting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise; the LVAD market projected to nearly double by 2032; and tecarfarin having the potential to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to utilize Abbott's expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal clinical trial for tecarfarin in LVAD patients by Cadrenal; for tecarfarin to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. (Tables to Follow) Cadrenal Therapeutics, Inc. Balance Sheets March 31, 2025 (unaudited) Assets: Current assets: Cash and cash equivalents $ 7,336,072 $ 10,017,942 Interest receivable 24,664 38,153 Prepaid expenses and other current assets 575,605 42,257 Deferred offering costs 8,451 14,445 Total current assets 7,944,792 10,112,797 Property, plant and equipment, net 4,678 6,944 Other assets 3,792 3,792 Total assets $ 7,953,262 $ 10,123,533 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable $ 1,278,402 $ 1,502,468 Accrued liabilities 561,764 1,181,490 Total current liabilities 1,840,166 2,683,958 Total liabilities 1,840,166 2,683,958 Stockholders' equity: Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding at March 31, 2025 and December 31, 2024 - - Common stock, $0.001 par value; 75,000,000 shares authorized, 1,909,732 shares issued and outstanding as of March 31, 2025; 1,782,486 shares issued and outstanding as of December 31, 2024 1,909 1,782 Additional paid-in capital 35,679,350 33,160,576 Accumulated deficit (29,568,163 ) (25,722,783 ) Total stockholders' equity 6,113,096 7,439,575 Total liabilities and stockholders' equity $ 7,953,262 $ 10,123,533 Expand (1) All share and per share information has been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on August 20, 2024. Expand
Associated Press
15-04-2025
- Health
- Associated Press
CVD researcher/clinician named Editor-in-Chief of Circulation: Genomic and Precision Medicine
( NewMediaWire ) - April 15, 2025 - DALLAS — Ferhaan Ahmad, M.D., Ph.D., FAHA, is the new editor-in-chief of Circulation: Genomic and Precision Medicine, a peer-reviewed scientific journal published by the American Heart Association, effective with the journal's April issue, published today. Ahmad is the founding director of the Cardiovascular Genomics Program and associate professor of internal medicine-cardiovascular medicine at the University of Iowa Carver College of Medicine in Iowa City, Iowa. He takes the helm leading Circulation: Genomic and Precision Medicine from Kiran Musunuru, M.D., Ph.D., M.P.H, FAHA, who served as interim editor-in-chief since April 2024. 'Dr. Ahmad's extensive cardiology expertise and leadership in the field of cardiovascular genomics, his commitment to innovation and drive for scientific advances will guide Circulation: Genomic and Precision Medicine to new heights as the specialty continues to evolve,' said Eldrin F. Lewis, M.D., M.P.H., FAHA, volunteer chair of the American Heart Association's Scientific Publishing Committee, which oversees the Association's 14 peer-reviewed scientific journals. Lewis is the Simon H. Stertzer, M.D., Professor of Cardiovascular Medicine and chief of the division of cardiovascular medicine at Stanford University in Stanford, California. Ahmad most recently served as an associate editor and senior associate editor of the Journal of the American Heart Association (JAHA) for the past 10 years. He stepped down from JAHA to assume his new role with Circulation: Genomic and Precision Medicine. 'Thank you to Dr. Ahmad for his integral role in advancing JAHA's impact and reputation for scientific excellence over the last decade,' said Lewis. Ahmad's additional roles at the University of Iowa include associate professor of molecular physiology and biophysics, associate professor of radiology and director of the Cardiovascular Disease Fellowship Training Program. He also leads a laboratory conducting basic and translational research into the genetic and genomic mechanisms underlying inherited cardiovascular disorders, including hypertrophic cardiomyopathy, dilated cardiomyopathy, glycogen storage cardiomyopathy, inherited arrhythmias and pulmonary hypertension, and the mechanisms by which the SGLT1 protein contributes to heritable and acquired heart failure. Ahmad's clinical expertise includes coronary artery disease, cardiomyopathy and other inherited cardiovascular conditions, and he continues to mentor countless postdoctoral fellows and medical, graduate and undergraduate students. 'Cardiovascular genetics combined with genomics is a quickly evolving field that is highly dependent on the contributions of many professionals from various disciplines, and advances are emerging quickly,' said Ahmad. 'In my new role as editor-in-chief, I am excited to build on the journal's success while elevating the inclusion of studies that advance implementation science, community-engaged/community-based participatory research, as well as papers highlighting equitable health and social drivers of health. These are critical areas to understanding the genetic and genomic basis of cardiovascular and cerebrovascular disease. Translating these findings to practice is key to improving care and outcomes for patients,' said Ahmad. Ahmad also plans to champion initiatives that strengthen the journal's position within the specialty, such as: Ahmad earned his doctor of medicine degree at McGill University in Montreal, Canada, followed by postgraduate clinical training at McGill University, Baylor College of Medicine in Houston and the Brigham and Women's Hospital in Boston. He subsequently earned a Ph.D. in human genetics from Baylor College of Medicine and completed a Howard Hughes Medical Institute postdoctoral fellowship in mouse genetics at Harvard Medical School. In addition to his role with JAHA, Ahmad has served in several leadership roles in the American Heart Association's Council on Genomic and Precision Medicine, the Council on Epidemiology and Prevention, and the Committee for Scientific Sessions Programming. He also serves on the Association's Hypertrophic Cardiomyopathy Science Advisory Group. Ahmad has received numerous research grants and is active in several clinical trials of novel therapies for heritable cardiomyopathies. He has co-authored more than 60 published, peer-reviewed research articles including serving as the chair of the writing group for the 2019 American Heart Association Scientific Statement, " Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards.' He also authored the chapter on cardiovascular genetics in the American College of Cardiology Self-Assessment Program (ACCSAP). Circulation: Genomic and Precision Medicine, which launched in 2008, is the leading scientific journal for original research detailing mechanistic, diagnostic, prognostic and therapeutic advances in genetics and genomics, including studies in human subjects, laboratory animals, in vitro and in silico, focused on relevance to human cardiovascular biology and disease. Areas of interest include investigations of clinical genetics as applied to cardiovascular disorders, the molecular basis of complex cardiovascular disorders, and novel applications of precision medicine. The online-only journal publishes six issues per year, and accepted articles are published online ahead of issue. Circulation: Genomic and Precision Medicine is part of the American Heart Association's portfolio of 14 peer-reviewed scientific journals: Circulation; Stroke; Hypertension; Journal of the American Heart Association; Arteriosclerosis, Thrombosis, and Vascular Biology; Circulation Research; Circulation: Arrhythmia and Electrophysiology; Circulation: Heart Failure; Circulation: Cardiovascular Imaging; Circulation: Cardiovascular Interventions; Circulation: Cardiovascular Quality and Outcomes; Stroke: Vascular and Interventional Neurology; and Annals of Internal Medicine: Clinical Cases. Each journal is editorially independent of one another and the Association in support of open dialogue and discourse, which are essential to the dynamic nature of scientific discovery. Editors-in-chief are selected by the Association's volunteer-led Scientific Publishing Committee, and each editor-in-chief assembles and manages the editorial board, vision and strategy for their journal. The Association is the publisher of the journals; however, the Association has no oversight on the science content published. Studies published in the American Heart Association's scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content. Overall financial information is available here. Additional Resources: ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: 214-706-1173 Michelle Kirkwood: [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and
